S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   327.99 (+0.79%)
AAPL   142.79 (+2.67%)
MSFT   229.21 (+1.44%)
FB   278.00 (+1.28%)
GOOGL   1,893.49 (+0.05%)
AMZN   3,299.67 (+0.23%)
TSLA   879.97 (+3.94%)
NVDA   545.79 (-0.49%)
BABA   262.06 (+1.33%)
CGC   32.63 (-3.46%)
GE   10.97 (-1.26%)
MU   81.16 (-1.36%)
AMD   94.06 (+1.37%)
NIO   60.16 (-2.89%)
T   29.08 (+0.52%)
F   11.28 (-2.08%)
ACB   10.13 (-4.88%)
BA   202.77 (-1.49%)
DIS   172.12 (-0.38%)
NFLX   556.54 (-1.53%)
GILD   68.06 (+1.67%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   327.99 (+0.79%)
AAPL   142.79 (+2.67%)
MSFT   229.21 (+1.44%)
FB   278.00 (+1.28%)
GOOGL   1,893.49 (+0.05%)
AMZN   3,299.67 (+0.23%)
TSLA   879.97 (+3.94%)
NVDA   545.79 (-0.49%)
BABA   262.06 (+1.33%)
CGC   32.63 (-3.46%)
GE   10.97 (-1.26%)
MU   81.16 (-1.36%)
AMD   94.06 (+1.37%)
NIO   60.16 (-2.89%)
T   29.08 (+0.52%)
F   11.28 (-2.08%)
ACB   10.13 (-4.88%)
BA   202.77 (-1.49%)
DIS   172.12 (-0.38%)
NFLX   556.54 (-1.53%)
GILD   68.06 (+1.67%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   327.99 (+0.79%)
AAPL   142.79 (+2.67%)
MSFT   229.21 (+1.44%)
FB   278.00 (+1.28%)
GOOGL   1,893.49 (+0.05%)
AMZN   3,299.67 (+0.23%)
TSLA   879.97 (+3.94%)
NVDA   545.79 (-0.49%)
BABA   262.06 (+1.33%)
CGC   32.63 (-3.46%)
GE   10.97 (-1.26%)
MU   81.16 (-1.36%)
AMD   94.06 (+1.37%)
NIO   60.16 (-2.89%)
T   29.08 (+0.52%)
F   11.28 (-2.08%)
ACB   10.13 (-4.88%)
BA   202.77 (-1.49%)
DIS   172.12 (-0.38%)
NFLX   556.54 (-1.53%)
GILD   68.06 (+1.67%)
S&P 500   3,855.36 (+0.36%)
DOW   30,960.00 (-0.12%)
QQQ   327.99 (+0.79%)
AAPL   142.79 (+2.67%)
MSFT   229.21 (+1.44%)
FB   278.00 (+1.28%)
GOOGL   1,893.49 (+0.05%)
AMZN   3,299.67 (+0.23%)
TSLA   879.97 (+3.94%)
NVDA   545.79 (-0.49%)
BABA   262.06 (+1.33%)
CGC   32.63 (-3.46%)
GE   10.97 (-1.26%)
MU   81.16 (-1.36%)
AMD   94.06 (+1.37%)
NIO   60.16 (-2.89%)
T   29.08 (+0.52%)
F   11.28 (-2.08%)
ACB   10.13 (-4.88%)
BA   202.77 (-1.49%)
DIS   172.12 (-0.38%)
NFLX   556.54 (-1.53%)
GILD   68.06 (+1.67%)
Log in
NASDAQ:CDTX

Cidara Therapeutics Stock Forecast, Price & News

$2.56
+0.05 (+1.99 %)
(As of 01/25/2021 03:52 PM ET)
Add
Compare
Today's Range
$2.46
Now: $2.56
$2.58
50-Day Range
$2.00
MA: $2.19
$2.46
52-Week Range
$1.30
Now: $2.56
$4.45
Volume31,746 shs
Average Volume421,872 shs
Market Capitalization$112.48 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Cidara Therapeutics logo

MarketRank

Overall MarketRank

1.89 out of 5 stars

Medical Sector

96th out of 1,922 stocks

Biological Products, Except Diagnostic Industry

7th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDTX
CUSIPN/A
Phone858-752-6170
Employees68
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.92 million
Book Value$1.15 per share

Profitability

Net Income$-41,090,000.00
Net Margins-662.48%

Miscellaneous

Market Cap$112.48 million
Next Earnings Date3/3/2021 (Estimated)
OptionableOptionable
$2.56
+0.05 (+1.99 %)
(As of 01/25/2021 03:52 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cidara Therapeutics (NASDAQ:CDTX) Frequently Asked Questions

How has Cidara Therapeutics' stock price been impacted by COVID-19?

Cidara Therapeutics' stock was trading at $2.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CDTX stock has increased by 3.2% and is now trading at $2.56.
View which stocks have been most impacted by COVID-19
.

Is Cidara Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cidara Therapeutics stock.
View analyst ratings for Cidara Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cidara Therapeutics?

Wall Street analysts have given Cidara Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cidara Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cidara Therapeutics' next earnings date?

Cidara Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for Cidara Therapeutics
.

How were Cidara Therapeutics' earnings last quarter?

Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.01. The biotechnology company had revenue of $2.42 million for the quarter, compared to analyst estimates of $3.56 million. Cidara Therapeutics had a negative trailing twelve-month return on equity of 165.58% and a negative net margin of 662.48%.
View Cidara Therapeutics' earnings history
.

What price target have analysts set for CDTX?

4 analysts have issued 1-year price targets for Cidara Therapeutics' stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate Cidara Therapeutics' share price to reach $6.75 in the next twelve months. This suggests a possible upside of 163.7% from the stock's current price.
View analysts' price targets for Cidara Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Cidara Therapeutics' key competitors?

What other stocks do shareholders of Cidara Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU), Exelixis (EXEL), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and Catalyst Pharmaceuticals (CPRX).

Who are Cidara Therapeutics' key executives?

Cidara Therapeutics' management team includes the following people:
  • Dr. Jeffrey L. Stein, Pres, CEO & Exec. Director (Age 66, Pay $797.1k)
  • Mr. Neil Abdollahian M.B.A., M.S., Chief Bus. Officer (Age 48, Pay $550.1k)
  • Dr. Taylor Sandison, Chief Medical Officer (Age 49, Pay $568.3k)
  • Dr. Kevin M. Forrest Ph.D., Founder and Chief Strategy Officer (Age 44)
  • Mr. James E. Levine, Chief Financial Officer (Age 50)
  • Mr. Paul Daruwala, COO & Chief Commercial Officer (Age 52)
  • Mr. Brady Johnson, Principal Accounting Officer, Controller & Director of Fin.
  • Mr. Christopher A. Kurtz, Exec. VP of Technical Operations (Age 54)
  • Ms. Jessica Oien J.D., Gen. Counsel & Sec. (Age 50)
  • Dr. Kenneth F. Bartizal Ph.D., Chief Devel. Officer (Age 70)

When did Cidara Therapeutics IPO?

(CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

What is Cidara Therapeutics' stock symbol?

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

How do I buy shares of Cidara Therapeutics?

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cidara Therapeutics' stock price today?

One share of CDTX stock can currently be purchased for approximately $2.56.

How big of a company is Cidara Therapeutics?

Cidara Therapeutics has a market capitalization of $112.48 million and generates $20.92 million in revenue each year. The biotechnology company earns $-41,090,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe.

What is Cidara Therapeutics' official website?

The official website for Cidara Therapeutics is www.cidara.com.

How can I contact Cidara Therapeutics?

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.